Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

The FDA has designed five different types of labels, each presenting the same information but with different specifications based on the size of the packaging.

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

It’s one thing for the scientific community to propose a fundamental change to the way obesity is defined and diagnosed. But ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.